Clinical Trial Update: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. [Phase 3]

View source ↗

Summary

A Phase 3 global trial evaluating Lisaftoclax (APG-2575) in combination with acalabrutinib versus immunochemotherapy for newly diagnosed chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Lisaftoclax (APG-2575)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: CLL/SLL | Phase 3 | Status: RECRUITING